Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. Let's consider four ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next ...

U.S. energy firms seek exemption from Trump to transport LNG on U.S.-built ships. China Airlines orders Boeing passenger and ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Who is Casey Means, MD? A profile of the new nominee for U.S. Surgeon General. (AP) President Trump is expected to sign an ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

As we learn more about GLP-1 drugs like Wegovy and Zepbound, early research suggests that they may be able to improve COPD ...